Transvenous Cardiac Implantable Devices and Pulmonary Hypertension: An Echocardiographic Evaluation in a Cohort Study

Not Applicable

Active, not recruiting

• Conditions: Patients with cardiac implantable electronic devices; Permanent pacemakers; Implantable cardioverter defibrillators; Cardiac Resynchronization Therapy; Pulmonary Hypertension; Cardiovascular - Other cardiovascular diseases; Cardiovascular - Hypertension; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12620000999932
• Lead Sponsor: Centre for Heart Rhythm Disorders, University of Adelaide

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-06
• Last Update Posted: 12 October 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 1572

Inclusion Criteria

1. All patients who underwent CIED implantation between 2009 and 2017 will be reviewed for inclusion
2. The eligible participants will only be identified from a single centre (Centre for Heart Rhythm Hospital/Royal Adelaide Hospital)
3. The control participants are the age-matched patients who have not had a CIED implanted but who have had an annual echocardiogram follow-up

Exclusion Criteria

- patients without any follow-up of at least two echocardiograms (first within 6 months and the second greater than 1 year following implant)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the proportion of patients with pulmonary hypotension will be determined using echocardiogram data from each participant collected from historical electronic medical records between 2009 and 2017[yearly, up to 10 years post enrollment]

Secondary Outcome Measures

Name	Time	Method
factors associated with development of pulmonary hypertension from historical medical records between 2009 and 2017<br>[yearly, up to 10 years post-enrollment];factors associated with the development of right ventricular dysfunction from historical medical records between 2009 and 2017[yearly, up to 10 years post-enrollment]